¹«Á¦ ¹®¼­
 
   
¹«Á¦ ¹®¼­
 
 
 
 
 
³¯Â¥ 2010-12-02
Á¦¸ñ Scrip Intelligence
³»¿ë Scrip May 25th 2007

Headlines
*Amgen to appeal CHMP's negative stance on Vectibix
*BTG comes through cost cuts with extra cash for research & development
*China edges forward on intellectual property in US talks
*CHMP gives green light to Roche's Mircera
*Danish agency rules out generic prescription
*Disgruntled Apotex finally launches its generic Norvasc
*EMEA (European Medicines Agency) restricts bicalutamide 150mg to high-risk patients
*GlaxoSmithKline set to launch research & development operations in China
*Ixico raises £2.44 million in investments
*Jobs go as CV Therapeutics sticks with Ranexa
*KV's Clindesse email alert overstates efficacy FDA says
*MEPs say no to EU directive on health services
*No counterfeits in French supply chain says regulator
*Parallel trade blamed for UK counterfeit Zyprexa
*Pharma wants agencies to conduct joint manufacturing inspections
*Pharmaceutical spending on the rise in Spain:
*Tercica's Increlex among latest EU positive opinions
*US FDA panel to review Evista for reducing breast cancer risk:
*US FDA warning Enzon over Abelcet promotion
*US growth for Abilify drives Otsuka
*US rejects Brazilian resolution on access to medicines
*Velcade/Doxil combination approved for multiple myeloma in the US

°ü·ÃURL : http://www.scrippharma.com

 
 
 
   
¹«Á¦ ¹®¼­